Liberty Wealth Management LLC Purchases Shares of 18,170 Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Liberty Wealth Management LLC acquired 18,170 shares of Gilead Sciences, Inc., valued at approximately $2,036,000, marking a significant investment during the first quarter.
• Several institutional investors have increased their stakes in Gilead Sciences, leading to 83.67% of the stock being held by these investors.
• Research firms are optimistic about Gilead Sciences, with eight analysts rating the stock as 'hold', fifteen as 'buy', and three as 'strong buy', indicating a positive market sentiment.

Liberty Wealth Management LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,170 shares of the biopharmaceutical company's stock, valued at approximately $2,036,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $29,000. Core Alternative Capital lifted its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares in the last quarter. IMA Advisory Services Inc. acquired a new position in shares of Gilead Sciences during the first quarter worth $39,000. Finally, Investment Research & Advisory Group Inc. lifted its position in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on GILD. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Oppenheimer cut their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Eight investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $112.36.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $277,575.00. Following the sale, the chief financial officer owned 162,610 shares of the company's stock, valued at $18,054,588.30. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $8,984,175 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 0.8%

GILD stock opened at $113.18 on Monday. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences, Inc. has a 1-year low of $72.43 and a 1-year high of $119.96. The firm has a fifty day moving average price of $110.51 and a two-hundred day moving average price of $106.91. The firm has a market cap of $140.79 billion, a price-to-earnings ratio of 23.83, a PEG ratio of 0.71 and a beta of 0.33.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.